The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
Mike I. Walton(Institute of Cancer Research), Michelle D. Garrett(Institute of Cancer Research)
Cited by 69
Related Papers
No related papers found
Powered by citation graph analysis